Spotting: What Could Be Causing It and When to See a Doctor

What Is Spotting, Exactly?

Spotting is light vaginal bleeding that does not meet the volume threshold of a normal menstrual flow, typically defined as blood loss below 5 mL per episode. It may appear as pink, red, or brown discharge on underwear or toilet tissue, and it does not require a pad or tampon.

The FIGO PALM-COEIN classification, adopted by the American College of Obstetricians and Gynecologists, organizes abnormal uterine bleeding into structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) [1]. Spotting can arise from any of these categories, which is why a systematic differential is necessary before attributing it to a single explanation.

Hormonal and Contraceptive Causes

Hormonal fluctuations are the single most common driver of spotting in reproductive-age women. Both excess and deficient estrogen or progesterone can disrupt endometrial stability.

Combined Oral Contraceptive Pills (OCPs)

Breakthrough bleeding on combined OCPs occurs in approximately 30 to 50% of women during the first pill pack and declines to 10 to 30% by the third cycle [2]. The mechanism is endometrial thinning from synthetic progestin, which reduces stromal support for the superficial capillary layer. Consistent daily pill-taking at the same time reduces, but does not eliminate, this risk.

Low-dose pills containing 20 mcg ethinyl estradiol carry a higher breakthrough-bleeding rate than 30 to 35 mcg formulations. Switching to a higher estrogen dose or a different progestin (e.g., norethindrone to desogestrel) may resolve persistent spotting within one to two cycles.

Progestin-Only and Long-Acting Reversible Contraceptives

The levonorgestrel 52 mg intrauterine device (Mirena) causes irregular spotting in up to 23% of users at 3 months; this rate falls to roughly 3% by 12 months as the endometrium atrophies [3]. The etonogestrel implant (Nexplanon) produces unpredictable bleeding in about 17% of users, which is the leading reason for early removal per FDA prescribing data.

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) causes irregular spotting in 70% of users in the first year. After 12 months, approximately 50% achieve amenorrhea [4].

Perimenopause and Estrogen Fluctuation

In the menopausal transition, irregular anovulatory cycles cause estrogen levels to swing without the stabilizing effect of a predictable progesterone surge. This produces erratic, often light bleeding between cycles. The SWAN longitudinal cohort documented that 90% of women experience at least one episode of irregular bleeding in the 4 years surrounding the final menstrual period [5].

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism alter sex hormone-binding globulin and GnRH pulsatility, disrupting cycle regularity. TSH outside the normal range of 0.4 to 4.0 mIU/L is an independent predictor of intermenstrual bleeding in reproductive-age women [6].

Pregnancy-Related Causes

Any woman of reproductive age with unexplained spotting should have a urine or serum beta-hCG measured on the same visit, before imaging or further workup, because pregnancy changes the entire diagnostic and management tree.

Implantation Bleeding

Implantation bleeding occurs when the embryo invades the endometrial stroma, typically 6 to 12 days after fertilization. It affects roughly 25% of pregnancies and lasts one to two days at most [7]. The bleeding is lighter than a period, often described as pink or rust-colored. No treatment is needed; however, distinguishing implantation bleeding from a threatened miscarriage requires a confirmatory rise in beta-hCG (expected to approximately double every 48 hours in a viable intrauterine pregnancy).

Threatened Miscarriage

Spotting with a confirmed intrauterine pregnancy and a closed cervical os on exam is classified as a threatened miscarriage. This complicates 20 to 25% of all recognized pregnancies [8]. About half will progress to a complete miscarriage; the other half will continue to term. Progesterone supplementation (micronized progesterone 400 mg vaginally twice daily) reduced miscarriage risk in the PRISM trial (N=4,153) among women with spotting and a history of prior loss, with a live birth rate of 72% versus 67% in the placebo group (adjusted OR 1.09, 95% CI 0.97 to 1.21) [9].

Ectopic Pregnancy

An ectopic pregnancy causes spotting along with unilateral pelvic pain in a woman with a positive beta-hCG and no intrauterine gestational sac on TVUS. This is a medical emergency. The rate is approximately 1 to 2 per 100 pregnancies; rupture carries a maternal mortality risk that accounts for 2.7% of pregnancy-related deaths in the United States per CDC surveillance data [10]. Serum beta-hCG above the discriminatory zone (typically 1,500 to 2,000 mIU/mL) with no intrauterine sac mandates emergent gynecologic evaluation.

Structural Uterine and Cervical Causes

When hormonal and pregnancy causes are excluded, structural pathology rises to the top of the differential. The framework below organizes these by anatomic location, from cervix outward to uterine cavity.

Cervical Causes

Cervicitis. Inflammation from Chlamydia trachomatis or Neisseria gonorrhoeae produces a friable, easily traumatized cervix that bleeds on contact or spontaneously. The CDC estimates that 2.4 million chlamydia cases occur annually in the United States, with young women aged 15 to 24 carrying the highest burden [11]. Spotting from cervicitis is often post-coital. First-line treatment per CDC 2021 STI Treatment Guidelines is doxycycline 100 mg twice daily for 7 days for chlamydia or ceftriaxone 500 mg IM once for gonorrhea.

Cervical Ectropion. Columnar epithelium from the endocervical canal extends onto the ectocervix, creating a zone that bleeds easily on contact. This is common in adolescents, OCP users, and pregnant women. It is a benign anatomic variant that typically requires no treatment unless contact bleeding is bothersome; cryotherapy is then an option.

Cervical Polyps. Endocervical polyps are benign finger-like projections that produce intermittent spotting, particularly post-coital. They are visible on speculum exam and removed in-office by avulsion. Histologic examination is recommended to exclude rare malignant change.

Uterine Causes

Endometrial Polyps. Polyps are focal overgrowths of endometrial glands and stroma. They are the most common cause of intermenstrual bleeding in women over 40, found in 20 to 25% of women undergoing evaluation for abnormal uterine bleeding [12]. TVUS with saline infusion sonohysterography (SIS) has a sensitivity of 88 to 99% for polyp detection. Treatment is hysteroscopic polypectomy.

Submucosal Fibroids. Type 0 and Type 1 submucosal leiomyomata distort the uterine cavity and impair hemostasis of the overlying endometrium. They are identified in approximately 5 to 10% of women with abnormal uterine bleeding. MRI is the gold standard for fibroid mapping before surgical planning.

Adenomyosis. Endometrial glands embedded in the myometrium cause a boggy, tender uterus and heavy, irregular bleeding. Diagnosis is clinical and sonographic; MRI shows junctional zone thickness above 12 mm as a reliable marker. A 2021 systematic review in the American Journal of Obstetrics and Gynecology (N=1,978 patients across 14 studies) reported TVUS sensitivity of 83.8% and specificity of 63.9% for adenomyosis [13].

Ovulatory Dysfunction and Midcycle Spotting

Ovulatory spotting, sometimes called Mittelschmerz-associated bleeding, occurs at the LH surge when estrogen drops briefly before progesterone rises. This midcycle spotting is light, lasts less than 3 days, and occurs consistently around cycle day 12 to 16.

Polycystic ovary syndrome (PCOS) causes chronic anovulation, producing endometrial buildup that intermittently sheds as irregular, unpredictable spotting. Per the 2023 International Evidence-Based Guideline for PCOS, anovulatory bleeding is the most common menstrual presentation in PCOS, with cycle lengths ranging from 35 days to 6 months between episodes [14]. Progestin withdrawal therapy (medroxyprogesterone acetate 10 mg daily for 10 days) can induce a controlled shed, and cyclical progestin or an OCP prevents ongoing unopposed estrogen stimulation.

Hyperprolactinemia suppresses GnRH pulsatility and causes luteal phase deficiency, manifesting as spotting in the days before the expected period. Serum prolactin measurement is part of the standard workup for any woman with irregular spotting and a negative pregnancy test.

Postmenopausal Spotting: A Different Risk Profile

Any vaginal bleeding that occurs 12 or more months after the final menstrual period is postmenopausal bleeding (PMB) and must be evaluated promptly. The risk of endometrial malignancy is real.

Prevalence of Cancer in PMB

Endometrial cancer is the underlying diagnosis in approximately 9% of women presenting with PMB [15]. Atrophic vaginitis or endometritis accounts for roughly 60 to 80% of cases, so most postmenopausal bleeding is benign, but the 9% figure is high enough that workup cannot be deferred.

Diagnostic Pathway for PMB

ACOG Practice Bulletin No. 149 recommends TVUS as the initial diagnostic test. An endometrial stripe of 4 mm or less has a negative predictive value of approximately 99% for endometrial cancer in a woman with PMB [16]. Stripe above 4 mm, or any visible intrauterine lesion, requires endometrial sampling by office biopsy (Pipelle aspiration) or hysteroscopy.

As stated in ACOG Practice Bulletin No. 149: "In a postmenopausal woman with bleeding, the endometrial thickness measurement of 4 mm or less has a high negative predictive value for endometrial carcinoma and can be used to reassure patients and avoid invasive testing in low-risk cases" [16].

Spotting on Hormone Therapy (HT)

Women on systemic menopausal hormone therapy using a continuous combined regimen (estrogen plus progestin daily without a break) commonly experience irregular spotting for the first 3 to 6 months as the endometrium transitions to atrophy. The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement notes that unscheduled bleeding persisting beyond 6 months on continuous combined HT, or any bleeding that starts after a period of amenorrhea, warrants endometrial evaluation [17].

Women using sequential HT (estrogen daily, progestin for 10 to 14 days per month) should expect a scheduled withdrawal bleed. Spotting outside that window, or a bleed that begins earlier than day 10 of the progestin phase, is considered unscheduled and prompts investigation.

Spotting in Transgender and Gender-Diverse Patients on Gender-Affirming Hormone Therapy

Testosterone therapy in transmasculine individuals typically produces amenorrhea within 6 months, though timeline varies. Breakthrough spotting during testosterone therapy may indicate a subtherapeutic trough level (target serum total testosterone 400 to 700 ng/dL per Endocrine Society guidelines), endometrial pathology from prolonged estrogen exposure before therapy, or an unrelated structural cause [18]. Vaginal atrophy from testosterone-related hypoestrogenism increases tissue friability and can also produce contact spotting.

The Diagnostic Workup: A Stepwise Approach

A structured workup prevents premature closure on the most obvious diagnosis.

Step 1: Focused History

Collect: last menstrual period date, cycle regularity for the past 6 months, all medications including any OCP or hormonal therapy, sexual history, obstetric history, and any prior abnormal Pap smears. Note whether spotting is post-coital, midcycle, pre-menstrual, or random.

Step 2: Point-of-Care Tests

Order a urine beta-hCG immediately. If positive, pivot to the pregnancy differential. CBC if heavy bleeding is described. STI NAAT swab for gonorrhea and chlamydia if risk factors are present. TSH if cycle irregularity has been present for more than 3 months.

Step 3: Physical Exam

Bimanual pelvic exam assesses uterine size, tenderness, and adnexal masses. Speculum exam identifies cervical lesions, discharge, or ectropion. Cervical os status (open vs. Closed) is critical if pregnancy is confirmed.

Step 4: Imaging

TVUS is the first-line imaging modality for all ages. Saline infusion sonohysterography (SIS) adds diagnostic precision for intracavitary lesions. MRI is reserved for fibroid mapping or when adenomyosis is suspected and surgical management is being planned.

Step 5: Endometrial Sampling

Office endometrial biopsy (Pipelle) should be performed in any woman age 45 or older with abnormal uterine bleeding, or in younger women with risk factors for endometrial hyperplasia (obesity with BMI <30 is not protective; obesity with BMI above 30 increases risk), chronic anovulation, or tamoxifen use. The sensitivity of Pipelle biopsy for detecting endometrial cancer is 99.6% when the cancer is global; it falls to approximately 46% for focal lesions, so hysteroscopy is preferred when focal pathology is suspected [19].

Treatment Options by Cause

Treatment maps directly to the underlying diagnosis. There is no one-size approach.

| Cause | First-Line Treatment | Second-Line / Refractory | |---|---|---| | OCP breakthrough bleeding | Reassure if <3 months; consider higher estrogen dose | Switch progestin class | | LNG-IUD spotting | Reassure; 90% resolve by 12 months | Add short-course estradiol 1 mg x 7 days [3] | | Chlamydia cervicitis | Doxycycline 100 mg BID x 7 days | Re-test at 3 months; partner treatment | | Endometrial polyp | Hysteroscopic polypectomy | N/A (definitive) | | Submucosal fibroid | Hysteroscopic myomectomy | GnRH agonist (leuprolide) preoperatively | | PCOS anovulatory bleeding | Cyclic progestin or combined OCP | Metformin if insulin resistant | | Threatened miscarriage | Pelvic rest; micronized progesterone 400 mg BID vaginally if prior loss | Serial beta-hCG and TVUS | | Postmenopausal atrophic vaginitis | Topical vaginal estradiol 10 mcg suppository 2x/week | Ospemifene 60 mg daily | | Endometrial hyperplasia (without atypia) | Levonorgestrel IUD or oral progestin 6 months | Repeat biopsy at 6 months | | Endometrial cancer | Surgical staging (total hysterectomy, BSO, lymph node evaluation) | Adjuvant radiation or chemotherapy per FIGO stage |

When to Seek Care the Same Day

Most spotting is not an emergency. These situations are exceptions and require same-day or emergency evaluation:

• Positive pregnancy test plus pelvic pain plus spotting: rule out ectopic pregnancy.
• Heavy bleeding (soaking more than one pad per hour for two or more consecutive hours) with lightheadedness: hemorrhagic emergency.
• Postmenopausal bleeding in a woman who has never been evaluated for it: same-week evaluation is appropriate; same-day if bleeding is heavy.
• Fever plus spotting plus pelvic tenderness: pelvic inflammatory disease or septic abortion requires urgent antibiotic therapy and possible hospitalization.

The American College of Emergency Physicians recommends that any hemodynamically unstable patient with vaginal bleeding receive IV access, type and screen, and emergent gynecologic consultation before imaging [20].